Clinical-stage biotech company Shanton Pharma on Monday announced that it will be presenting topline data of a phase 2b study of refractory gout patients at the EULAR Congress in Barcelona on 14 June.

The European Alliance of Associations for Rheumatology (EULAR) congress will be held in Barcelona from 11-14 June 2025. The review committee and board have accepted Shanton's late-breaking abstract on the outcomes of its phase 2b study in refractory gout patients with its lead investigational drug SAP-001.

"We are excited to present our phase 2b topline data to the global rheumatology community at EULAR," commented Dr. Wenfeng Miao, Shanton's CMO. "We know that medical practitioners have long been looking for a new mechanism in gout management for their difficult-to-treat patients, and we believe that our programme that targets a distinct renal transporter, has the potential to offer a much-needed solution for those patients that do not respond to or cannot tolerate Standard-of-Care treatment with conventional Urate Lowering Therapies."